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Abstract 
Background and aim: Several studies have shown that bariatric surgery reduces long term mortality compared to 
medical weight loss therapy. In a previous study we have demonstrated that gastric banding (LAGB) is associated 
with reduced mortality in patients with and without diabetes, and with reduced incidence of obesity co-morbidities 
(cardiovascular disease, diabetes, and cancer) at a 17 year follow-up. The aim of this study was to verify at a longer 
time interval (23 years) mortality and incidence of co-morbidities in patients undergoing LAGB or medical weight loss 
therapy.
Patients and methods: As reported in the previous shorter-time study, medical records of obese patients [body 
mass index (BMI) > 35 kg/m2 undergoing LAGB (n = 385; 52 with diabetes) or medical treatment (controls, n = 681; 
127 with diabetes), during the period 1995–2001 (visit 1)] were collected. Patients were matched for age, sex, BMI, and 
blood pressure. Identification codes of patients were entered in the Italian National Health System Lumbardy data-
base, that contains life status, causes of death, as well as exemptions, prescriptions, and hospital admissions (proxies of 
diseases) from visit 1 to June 2018. Survival was compared across LAGB patients and matched controls using Kaplan–
Meier plots adjusted Cox regression analyses.
Results: Final observation period was 19.5 ± 1.87 years (13.4–23.5). Compared to controls, LAGB was associated with 
reduced mortality [HR = 0.52, 95% CI 0.33–0.80, p = 0.003], significant in patients with diabetes [HR = 0.46, 95% CI 
0.22–0.94, p = 0.034], borderline significant in patients without diabetes [HR = 0.61, 95% CI = 0.35–1.05, p = 0.076]. 
LAGB was associated with lower incidence of diabetes (15 vs 75 cases, p = 0.001), of CV diseases (61 vs 226 cases, 
p = 0.009), of cancer (10 vs 35, p = 0.01), and of renal diseases (0 vs 35, p = 0.001), and of hospital admissions (92 vs 
377, p = 0.001).
Conclusion: The preventive effect of LAGB on mortality is maintained up to 23 years, even with a decreased efficacy 
compared with the shorter-time study, while the preventive effect of LAGB on co-morbidities and on hospital admis-
sions increases with time.
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Introduction
Patients with obesity undergoing bariatric surgery have 
a longer life expectancy than patients receiving medical 
treatment of obesity. Several papers [1–8], analyzed in 
two meta-analyses [9, 10], have shown lower long-term 
mortality with bariatric surgery in comparison with non-
surgical controls; further, reduced mortality is observed 
in patients with and without diabetes [1, 4, 11, 12]. In 
addition, bariatric surgery improves quality of life in 
morbid obesity [13], is associated with lower develop-
ment of medical complications of obesity, reduced fre-
quency of co-morbidities, improved cardiovascular (CV) 
risk profile [14–20], and is cost-effective in the manage-
ment of obesity [21, 22]. The majority of studies has been 
performed through well established restrictive or mixed 
techniques [gastric banding (LAGB), vertical banded 
gastroplasty (VGB), roux-en-y gastric bypass (RYGB)], 
but recent studies have shown that laparoscopic sleeve 
gastrectomy (LSG) [23], as well as malabsorptive surgery 
[biliointestinal bypass (BIBP) and biliopancreatic diver-
sion (BPD)] is associated with reduced mortality and 
lower development of obesity related co-morbidities, 
compared to medical weight loss treatment of obesity 
[24].
No intermediate evaluation of clinical and metabolic 
effects of bariatric surgery, in comparison with medical 
treatment of obesity, has appeared in previous studies 
evaluating long-term mortality, so that reduced mortality 
seems an all-or-none effect, with no mechanistic expla-
nation for the reduced mortality.
In a previous retrospective study we have shown that, 
up to 17  years, LAGB is associated with reduced mor-
tality in patients with and without diabetes, and with 
reduced incidence of diabetes and cardiovascular dis-
eases [11]. This was the longest follow-up study, with 
no patient lost to follow-up; we also hypothesized that a 
longer follow-up was required to establish if the effects 
of LAGB were maintained or even made more significant 
through a prolonged observation, or whether the effects 
of LAGB vanished, also because of the process of aging.
The aim of this retrospective study was to extend the 
follow-up period observation of the previous study up to 
23 years. In addition, we had the opportunity to compare 
the intermediate clinical and metabolic effects of bariat-
ric surgery and of medical treatment of obesity, thus eval-
uating a possible mechanistic explanation for the reduced 
mortality.
Methods
Patients and study protocol
The participating institutions offer surgical and medi-
cal treatment of obesity. The institutions belong to the 
LAGB10 study group [11], a spontaneous network of 
physicians and surgeons working with bariatric surgery 
in the Lumbardy Region (Italy); LAGB has been per-
formed here since 1995, according to NIH guidelines 
[25]. The specific study protocol was approved by four 
Ethics Committees in 2012, after the initial protocol had 
been approved in 1995, in 2002, and in 2006. Being a ret-
rospective study, informed consent was obtained from all 
individual participants included in the study who could 
be reached by interview, phone or letter. The details of 
the protocol have been previously published [11]. Briefly, 
we considered all patients with obesity (BMI > 40  kg/
m2 alone or BMI > 35  kg/m2 in the presence of co-mor-
bidities) aged 18–65  years, seeking medical advice and 
referred to the outpatients obesity clinics during the 
period 1995–2001, (first visit) undergoing thereafter 
LAGB, or medical weight loss treatment. After evalua-
tion of indications and contra-indications, patients were 
offered LAGB; several patients declined the offer, mainly 
because of reluctancy, lack of knowledge of the possible 
benefits, fear of surgery and of surgical complications, 
inability or unwillingness to comply with the anticipated 
change of lifestyle habits or with the program of sched-
uled visits. Patients who declined surgery for any reason, 
but agreed to be followed-up during medical treatment, 
were considered controls. All surgery and nonsurgical 
patients were treated with diet, and received standard 
care (education on eating behaviors, advice on diet and 
exercise, plus drug treatment for diabetes and hyperten-
sion when present). At least initially, all patients were 
evaluated under basal conditions and at 3-month inter-
vals with measurement of body weight and assessment 
of food intake through review of diet diaries; their sug-
gested diet was between 1000 and 1200  kcal/day for 
women and men (22% protein, 29% lipids, and 49% car-
bohydrates), respectively, with the aid of a dietitian. From 
the medical records, birthdate and age, baseline anthro-
pometric data (height, weight, BMI) systolic and diastolic 
blood pressure, heart rate, metabolic data (fasting blood 
glucose, glycated hemoglobin [HbA1c (%)], total choles-
terol, HDL-, and LDL-cholesterol, triglycerides, aspartate 
transferase [AST], alanine transferase [ALT], creatinine 
and eGFR [modified diet in renal disease calculation 
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equation] [26]), current medical treatments, clinical evi-
dence of coronary heart disease (CHD), retinopathy, 
were derived and tabulated. From the medical records it 
was also possible to evaluate later visits and lab exami-
nation, when present. Diagnosis of diabetes (type 2 dia-
betes) was established as already reported [27, 28], and 
diagnosis of coronary heart disease (CHD) was based on 
medical records.
Procedures
Patients were identified through personal identifica-
tion codes; codes were entered the Regional Lumbardy 
Administrative Database, and it was possible to ascertain 
whether patients were alive, were dead, or had moved to 
other regions. The National Health System (NHS) covers 
more than 95% of all hospital admissions, medical and 
surgical procedures and medical expenses of citizens [29] 
(Italian Survey 2012). The Regional Lumbardy Admin-
istrative Database contains since 1988 all pertinent data 
of all citizens, and this makes life status a clear finding, 
independently of participation in studies and of loss to 
follow-up. In particular, the Lumbardy database collects 
several information, including (1) an archive of residents 
who receive NHS assistance, reporting demographic 
and administrative data; (2) a database on diagnosis at 
discharge from public or private hospitals of the region; 
(3) a database on outpatient drug prescriptions reim-
bursable by the NHS; and (4) a database on outpatient 
visits, including visits in specialist ambulatory care and 
diagnostic laboratories accredited by the NHS. For each 
patient, these databases are linked through a single iden-
tification code.
In the Italian National Health System development 
of chronic diseases (diabetes mellitus, liver and car-
diovascular diseases, selected thyroid, renal, and lung 
diseases) yields the right to exemption from medical 
charges (exemptions), that means life-long free prescrip-
tions and examinations for the above diseases. There-
fore, together with hospital admissions, exemptions were 
considered a proxy of development of chronic diseases. 
For each patient, exemptions and hospital admissions 
after first visit were identified and dated. Through regis-
tries of surgeons and the Regional Lumbardy Adminis-
trative Database it was also possible to retrieve patients 
who had removal of LAGB and/or new bariatric surgery 
procedures. Through the health districts (ASL) patients 
belonged to, it was possible to track causes of death, and 
nature of hospital admissions and of exemptions. Data 
from health districts were cross-checked with data from 
the Lumbardy Database, to rule out inconsistencies and 
possible delays in transcriptions. This procedure has 
already been employed and validated in previous stud-
ies in Lumbardy, Italy [11, 30]. The limit date of June 30, 
2018 was established for all patients for deaths, admis-
sions, and exemptions. Causes of death, as well as exemp-
tions and hospital admissions were coded according to 
ICD-10 codes. Full details of the procedures are reported 
elsewhere [11, 24, 30].
Outcomes
Death rate and cause of death among patients with diabe-
tes (surgical vs nonsurgical) and among patients without 
diabetes (surgical vs nonsurgical); exemptions and hospi-
tal admissions among patients with and without diabetes 
(surgical vs nonsurgical). Analysis of survival and of other 
outcomes was carried out on an intention-to-treat basis, 
with no consideration for LAGB removal.
Statistical analysis
Data are shown as average values (± SD) for continuous 
variables or absolute numbers and frequencies for dis-
crete variables. Continuous variables were compared with 
the Student’s t-test. Frequencies were compared with 
the Fisher exact test. Surgical and nonsurgical patients 
were matched (with and without diabetes separately) 
with no attempt to match patients of the whole cohort. 
Group matching was made for sex, BMI (± 5  kg/m2), 
age (± 10  years), for systolic (± 5  mmHg), and diastolic 
(± 5 mmHg) blood pressure. The median age of matched 
patients was 42 years, and the mean ages were 31.8 ± 6.43 
and 51.8 ± 5.89, respectively. The proportion of dead 
patients was plotted through Kaplan–Meier curves, and 
differences in survival among subgroups were tested by 
the log-rank test. A multivariable analysis of risk factors 
for mortality was performed (Cox proportional hazards 
model), and used to plot Kaplan–Meier curves for sur-
gery versus nonsurgical patients; age, median age, pres-
ence of diabetes, sex, systolic blood pressure, eGFR, and 
presence of CHD were entered a priori. Proportionality 
among the survival rates and attributable factors in the 
Cox model was assessed by plotting the log [− log (sur-
vival function)] versus time. Statistical analyses were per-
formed with STATA 12.0 for MacIntosh.
Power calculation and sample size
Being a retrospective study, power calculation and sam-
ple size were only calculated to understand if the study 
was meaningful. Due to previous papers dealing with 
long-term prevention of mortality, showing effective-
ness of about 50% in comparison with non-surgery sub-
jects [9, 10], given a power = 80% and an alfa error 0.05, 
it was calculated that 500 surgery subjects with 30 fatal 
events and 1000 nonsurgical subjects with 90 fatal events 
were required to detect significant differences in the out-
comes [31, 32]. Similarly, given the high efficacy of bari-
atric surgeries in the long-term prevention of diabetes 
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and of cancer, [33–35], we estimated that the occurrence 
of 100 exemptions in 500 bariatric surgery subjects and 
300 exemptions in 1500 subjects undergoing dietary and 
medical treatment would be required to detect significant 
differences in the outcomes between the two groups [31, 
32]. This manuscript was prepared following the guide-
lines of the STROBE statement [36] (Additional file 1).
Results
The details of patients in the study were already pub-
lished in a previous publication [11], and now appear 
in Additional file  2: Table  S1. Observation period was 
19.5 ± 1.87  years (13.34–23.5). Mortality rate was 2.6, 
6.6, 10.1, and 13.4% in controls at 5, 10, 15, and 20 years, 
respectively; mortality rate was 0.8, 2.5, and 3.1, and 7.4% 
in LAGB patients at 5, 10, 15, and 20 years, respectively.
Figure  1 shows crude mortality curves in patients 
receiving LAGB as compared to controls receiving medi-
cal weight loss therapy, and Fig.  2a and b show crude 
mortality curves in patients without and with diabetes, 
respectively. The reduced mortality in surgical vs non-
surgical patients was significant in the whole cohort and 
in patients with diabetes, of borderline significance in 
patients without diabetes. During the first 5 years there 
were 4 deaths (1 above median age) in the surgery group 
and 18 deaths (17 above median age) in the nonsurgical 
group (NS). After exclusion of these patients, the HR was 
0.32 (95% CI 0.15–0.69), (Log rank = 0.003).
Figure  3a, b shows crude mortality curves in patients 
receiving LAGB as compared to controls receiving medi-
cal weight loss therapy, subdivided into aged < 42  years 
and aged > 42  years, respectively. The reduced mortal-
ity in surgical vs nonsurgical patients was significant 
in patients aged > 42  years, not significant in patients 
aged < 42  years. Table  1 shows causes of death in the 
whole cohort in the original study and in the follow-up 
study; causes of death were similar in the two observa-
tion periods, and the comparison between surgical vs 
nonsurgical patients had a reduced level of significance 
in the follow-up period, in agreement with the reduced 
overall effect on prevention of mortality.
Table  2 compares the 17  year and the 23  year effects 
of LAGB as opposed to medical weight loss therapy; the 
effect on reduced mortality decreases with time, while 
the effect on prevention of co-morbidities and the effect 
on prevention of hospital admissions increases with 
time.
Table  3 shows the clinical and metabolic effects of 
LAGB and medical weight loss therapy. The interval 
between baseline and follow-up data was 4.9 ± 3.63 years 
(mean ± SD), with no differences between surgery and 
nonsurgical patients. The effects were clearly different, 
with the noticeable exceptions of cholesterol (total, LDL-, 
and HDL-cholesterol).
Table  4 shows univariate and multivariate analy-
sis of risk factors for mortality in the current study as 
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Fig. 1 Mortality in surgical and in nonsurgical control patients, matched for age, sex, body mass index and blood pressure. Number of patients at 
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compared with the original study, and indicates that risk 
factors considered in the original study maintained their 
value in the follow-up study.
Discussion
To our knowledge, this study represents the longest 
follow-up evaluation of patients undergoing LAGB, a 
bariatric surgery, in comparison with patients receiving 
surgery
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Fig. 2 Mortality in surgical and in matched nonsurgical control patients divided into patients without (a) and with (b) diabetes. Number of patients 
at risk is indicated. Years = since visit 1
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weight loss medical treatment. With its up to 23 years 
duration of observation, this study adds about 6  years 
to our previous study, in the same cohort, studied in 
the same way. The main finding, in comparison with 
our previous study [11], is the somehow reduced effect 
on prevention of long-term mortality in comparison 
with our previous study; in contrast, the preventive 
effect of surgery on incident diseases increases, and 
Log rank = 0.162, 
HR =  1.98, 95% C.I. 0.76-5.14
surgery
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Fig. 3 Mortality in surgical and in matched nonsurgical control patients divided according to median age (42 years): a below median age; b above 
median age. Number of patients at risk is indicated. Years = since visit 1
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the preventive effect of surgery on hospital admissions 
increases. Therefore, it appears that the beneficial effect 
of LAGB continues up to 23  years, even with some 
differences; the effect on mortality decreases, even it is 
still significant, while the effect on general health status 
continues, and increases. Overall, as recently confirmed 
Table 1 Causes of  death in  surgery and  nonsurgical patients during  the  original study (observation period 
13.9 ± 1.87 years, mean ± SD, 10) and in the follow-up study (observation period 19.5 ± 1.88 years)
Group Original study p Follow-up study p
Surgery Nonsurgical Surgery Nonsurgical
CVD 5 22 0.001 8 32 0.029
Total non-CVD 7 43 0.001 18 58 0.019
Cancer 7 33 0.016 13 44 0.033
Liver 0 4 NS 2 4 NS
Lung 0 3 NS 1 4 NS
Infection 0 3 NS 1 4 NS
Endocrine 0 0 NS 0 1 NS
External 0 0 NS 1 1 NS
Total 12 65 0.001 26 90 0.001
Table 2 Comparison of mortality (HR with 95% CI), incident diseases, and hospital admissions in surgery and nonsurgical 
patients during  the  original study (observation period 13.9 ± 1.87  years, mean ± SD, 10) and  in  the follow-up study 
(observation period 19.5 ± 1.88 years)
a When no new incident diseases of hospital admissions were recorded, data from the original study are indicated
Original study p Follow-up study p
Mortality HR = 0.35, 95% CI 0.19–0.65 0.001 HR = 0.52, 95% CI 0.33–0.80 0.003
 In non-DM HR = 0.42, 95% CI 0.19–0.97 0.041 HR = 0.61, 95% CI = 0.35–1.05 0.076
 In DM HR = 0.34, 95% CI 0.13–0.87 0.025 HR = 0.46, 95% CI 0.22–0.94 0.034
 Below median age HR = 0.69, 95% CI 0.18–2.68 0.586 HR = 1.98, 95% CI 0.76–5.14 0.162
 Above median age HR = 0.29, 95% CI 0.14–0.58 0.001 HR = 0.38, 95% CI 0.23–0.65 0.001
Surgery Nonsurgical p Surgery Nonsurgical p
Incident diseases
 Diabetes 15 48 0.018 15 75 0.001
 Arterial hypertension 42 107 0.028 47 174 0.001
 CVD 10 17 NS 14 52 0.009
 Renal diseases 0 3 NS 0 35 0.001
 Liver diseases 8 18 NS 8 25 NS
 Cancer 4 17 NS 10 35 0.01
 Lung diseases 4 9 NS 4a 9a NS
 Metabolic diseases 4 13 NS 4a 13 NS
 Total 87 232 0.001 102 418 0.001
Hospital admissions
 Diabetes 14 33 NS 14 120 0.001
 CVD 34 69 NS 35 119 0.001
 Liver disease 4 11 NS 6 28 0.028
 Renal diseases 0 4 NS 0 8 NS
 Cancer 9 22 NS 10 44 0.005
 Lung diseases 5 18 NS 5a 18a NS
Metabolic diseases 5 12 NS 5a 12a NS
 Muscular and bone diseases 17 28 NS 17a 28a NS
 Total 88 197 0.04 92 377 0.001
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by recent 4–5  year studies performed through various 
surgical techniques (LGB, RYGB, LSG) [23], our data 
confirm that bariatric surgery is associated with lower 
mortality compared to medical weight loss treatment 
[9, 10]; also prevention of co-morbidities, especially 
diabetes mellitus, is possible for prolonged periods [27, 
33, 37, 38].
A greater effect on mortality in patients with dia-
betes than in patients without diabetes has already 
been reported [12], leading to the interpretation that 
the benefit is greater in more compromised patients. 
There are no explanations for these differences, though 
it seems reasonable to assume that the aging process 
dilutes the preventive effect of LAGB on mortality. 
In the swedish obesity study (SOS study) [37] it was 
observed that the preventive effect of surgery on inci-
dent co-morbidities increases with duration of follow-
up (from 2 to 10 years); our data support these findings, 
even though the observation periods of the two stud-
ies are quite different. However, we observed that the 
effect of surgery depends on age, i.e. it is significant for 
patients above median age (42 years in this cohort), not 
in younger patients. This confirms what was already 
observed by us and by others, using different bariatric 
Table 3 Variables evaluated at baseline and follow-up (4.9 ± 3.63 years)
Mean ± SD
BMI body mass index, HbA1c glycated hemoglobin, EGFR estimated glomerular filtration rate (mL/min/1.73 m2), AST aspartate transaminase, ALT alanine transaminase
Surgery (n = 154) p Nonsurgical (n = 360) p
Baseline Follow-up Baseline Follow-up
Age (years) 41.0 ± 10.13 – – 42.2 ± 12.94 – –
BMI (kg/m2) 42.7 ± 4.62 36.7 ± 5.24 0.0001 39.1 ± 5.27 39.1 ± 6.16 0.5047
Blood glucose (mg/dL) 108.6 ± 39.36 97.6 ± 32.09 0.0001 103.1 ± 27.40 103.6 ± 30.47 0.4452
Hba1c (%) 6.0 ± 1.35 5.5 ± 1.01 0.0001 7.6 ± 2.51 6.7 ± 1.64 0.1055
Systolic BP (mmHg) 133.8 ± 14.59 127.2 ± 12.38 0.0001 132.4 ± 13.36 132.8 ± 8.76 0.9090
Diastolic BP (mmHg) 83.9 ± 9.55 77.8 ± 8.68 0.0001 78.65 ± 9.48 78.8 ± 10.43 0.5203
Heart rate (bpm) 78.2 ± 5.95 55.7 ± 28.89 0.0304 71.2 ± 6.46 75.8 ± 10.56 0.1280
EGFR (mL/min/1.73 m2) 107.3 ± 29.07 99.3 ± 23.34 0.0010 85.4 ± 21.54 90.2 ± 18.83 0.0811
Cholesterol (mg/dL) 207.7 ± 43.77 203.2 ± 36.77 0.0685 210.5 ± 32.68 198.8 ± 37.43 0.0272
LDL-cholesterol (mg/dL) 130.6 ± 40.50 124.44 ± 32.60 0.0250 135.4 ± 35.07 119.3 ± 34.81 0.0214
HDL-cholesterol (mg/dL) 50.1 ± 13.52 54.6 ± 13.87 0.0001 48.4 ± 11.82 51.29 ± 12.29 0.0298
Triglycerides (mg/dL) 140.4 ± 76.49 122.2 ± 66.93 0.0001 139.2 ± 68.34 130.8 ± 52.72 0.1735
AST (U/L) 23.7 ± 11.86 21.5 ± 8.55 0.0146 23.6 ± 10.41 24.5 ± 7.26 0.2830
ALT (U/L) 31.3 ± 21.14 24.2 ± 15.39 0.0001 32.9 ± 27.64 30.4 ± 15.19 0.2568
Table 4 Univariate and multivariable analysis of risk factors for mortality (Cox proportional hazards model) in the whole 
sample Hazard ratios (HR, with 95% CI) and standard errors are indicated, together with effect (z) and significance level
In brackets values observed in the original study [10]
HR S.E. Z p 95% CI
Univariate analysis
 Surgery 0.52 (0.35) 0.12 (0.11) − 2.94 (− 3.33) 0.003 (0.001) 0.33–0.81 (0.19–0.65)
 Age > 42 years 5.53 (7.15) 1.45 (2.43) 6.52 (5.81) 0.001 (0.001) 3.31–9.26 (3.68–13.91)
 Female sex 0.53 (0.39) 0.10 (0.09) − 3.27 (− 4.02) 0.001 (0.001) 0.36–0.78 (0.25–0.62)
 Coronary heart disease 4.98 (4.67) 1.35 (1.52) 5.94 (4.73) 0.001 (0.001) 2.93–8.47 (2.47–8.86)
 Diabetes 3.94 (5.71) 0.74 (1.31) 7.29 (7.61) 0.001 (0.001) 2.73–5.70 (3.54–8.94)
Multivariable analysis
 Surgery 0.51 (0.41) 0.12 (0.13) − 2.95 (− 2.82) 0.003 (0.005) 0.33–0.80 (0.22–0.76)
 Age > 42 years 4.31 (4.35) 1.21 (1.57) 5.21 (4.08) 0.001 (0.001) 2.49–7.45 (2.15–8.82)
 Female sex 0.53 (0.39) 0.10 (0.09) − 3.25 (− 4.10) 0.001 (0.001) 0.36–0.78 (0.25–0.61)
 Coronary heart disease 2.83 (2.51) 0.78 (0.83) 3.77 (2.75) 0.001 (0.006) 1.65–4.87 (1.31–4.81)
 Diabetes 2.65 (3.11) 0.53 (0.75) 4.86 (4.69) 0.001 (0.001) 1.79–3.93 (1.93–4.99)
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techniques [5, 8, 11, 39]; in the SOS Study, patients 
aged < 37  years were intentionally excluded because of 
the low mortality of patients with obesity in young age 
[4].
This study has strengths and limitations; the main 
strength lies in the prolonged observation period of 
the same cohort, evaluated with the same approach; 
also, due to the methods employed, no patient was lost 
to follow-up. In addition, we had detailed description 
of causes of death of all patients, of incident diseases, 
of hospital admissions. More, we had the possibility to 
observe clinical and metabolic variables in a fair pro-
portion of patients after a mean period of 5 years, and 
we could observe a significant different effect of sur-
gery vs medical weight loss treatment. Obesity, and 
especially visceral obesity, favor development of car-
diovascular disease in type 2 diabetes [40], and both 
type 2 diabetes and obesity predict all-cause mortality 
[41, 42]; the present results indicate that LAGB, able 
to induce weight loss and to prevent diabetes, prevents 
mortality through improvement of the general health 
status [43]. Finally, as reported above, we confirmed a 
significant age-related effect on prevention of mortality, 
in agreement with previous studies [5, 8, 11, 39].
The main limitation lies in the retrospective nature 
of the study; the second limitation is that the study 
was not randomized, but at the time this study was 
conceived, randomization was deemed unethical, so 
that prospective studies could not be performed. The 
fact that several patients refused surgery for multi-
ple reasons might represent a selection bias; however, 
it should be emphasized that in the years 1995–2001 
evidence of benefits of bariatric surgery were still lim-
ited. Also, during the first 5 years there were 4 deaths (1 
above median age) in the surgery group and 18 deaths 
(17 above median age) in the nonsurgical group (NS); 
we have no explanation for a higher number of early 
deaths in both groups is higher than in previous papers 
[10], but differences in different cohorts can occur. The 
fourth limitation is in the sample size. The fifth limita-
tion is represented by the fact that the use of of LAGB 
is declining, so that some people argue LAGB should 
be abandoned; actually, LAGB is still performed in a 
significant proportion of patients with obesity. The last 
limitation is that our results can not be generalized to 
all bariatric procedures, also because there are no stud-
ies of similar duration performed with other bariatric 
techniques.
Conclusion
The preventive effect of LAGB on mortality is maintained 
up to 23 years, even with a decreased efficacy, while the 
preventive effect of LAGB on incident diseases and on 
hospital admissions increases with time. These data indi-
cate that the beneficial effects of LAGB is long lasting.
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